# Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

> **NCT06136910** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Untreated Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy

## Key facts

- **NCT ID:** NCT06136910
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-09
- **Primary completion:** 2024-05-09
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136910, "Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06136910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*